Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities Galapagos intends to create a new...
Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference Mechelen, Belgium; January 7, 2025, 22:01 CET; Galapagos NV (Euronext...
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with...
Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024 New Phase 1/2 data support the potential of our CAR...
Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update We are advancing our pipeline and accelerating innovation...
Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos...
Galapagos receives transparency notification from EcoR1 Capital Mechelen, Belgium; 30 September 2024, 22:01 CET; regulated information – Galapagos...
Galapagos receives transparency notification from EcoR1 Capital Mechelen, Belgium; 16 September 2024, 22:01 CET; regulated information – Galapagos...
Galapagos receives transparency notification from FMR LLC Mechelen, Belgium; 3 September 2024, 22:01 CET; regulated information – Galapagos NV...
Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin...
Galapagos receives transparency notification from FMR LLC Mechelen, Belgium; 20 August 2024, 22:01 CET; regulated information – Galapagos NV...
Galapagos reports half-year 2024 financial results and provides second quarter business update Executing on our Forward, Faster strategy with...
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024 Mechelen, Belgium; June 14...
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy...
Galapagos creates new subscription right plans Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads